Translational cancer research最新文献

{"title":"Bioinformatics analysis reveals <i>VEGFC</i>'s prognostic significance in head and neck squamous cell carcinoma and its association with immune cell infiltration.","authors":"Yulian Tang, Ting Hu, Wenli Yin, Changqiao Huang, Dewen Liu, Fengming Lai, Chengliang Yang, Lizhu Tang","doi":"10.21037/tcr-24-834","DOIUrl":"10.21037/tcr-24-834","url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) has a poor prognosis due to late diagnosis and complex molecular mechanisms. Vascular endothelial growth factor C (VEGFC) is associated with angiogenesis and lymphangiogenesis. This study aimed to investigate <i>VEGFC</i>'s prognostic value in HNSCC and its correlation with immune cell infiltration.</p><p><strong>Methods: </strong><i>VEGFC</i> gene expression was analyzed in HNSCC patients using Tumor Immune Estimation Resource 2.0 (TIMER2.0), Gene Expression Profiling Interactive Analysis (GEPIA), and University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) databases, focusing on differential expression and clinical-pathological correlations. The impact of <i>VEGFC</i> on overall survival (OS) and disease-free survival (DFS) was assessed using GEPIA. RNA-seq profiles and clinical information from 503 HNSCC tumor tissues and 44 normal control tissues obtained from The Cancer Genome Atlas (TCGA) database were subjected to univariate and multivariate Cox regression analyses to develop a prognostic nomogram. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was used for a protein-protein interaction (PPI) network, while the Tumor-Immune System Interaction Database (TISIDB) for immune-related associations. Expression was further validated with the Gene Expression Omnibus dataset (GSE6631) and reverse transcription quantitative polymerase chain reaction (RT-qPCR).</p><p><strong>Results: </strong><i>VEGFC</i> was significantly upregulated in HNSCC and closely correlated with age, gender, race, and tumor stage (P<0.05). PPI and co-expression gene analysis identified ITGA3, NT5E, and PXN as highly associated with VEGFC (R>0.6, P<0.05), which are mainly enriched in PI3K/Akt, MAPK signaling pathway, and cancer-associated glycoproteins. High <i>VEGFC</i> expression predicted poor OS (P=0.003) and DFS (P=0.03). Univariate and multivariate Cox regression analyses confirmed <i>VEGFC</i> as an independent prognostic factor for HNSCC. The prognostic nomogram accurately predicted 1-, 3-, and 5-year survival and calibration curve was very close to ideal 45-degree diagonal line. <i>VEGFC</i> also correlated with immune cells infiltration, including B cells, CD4⁺ T cells, CD8⁺ T cells, as well as immune-related markers such as tumor-infiltrating lymphocytes (TILs) markers, immune modulators, and inflammatory chemokines (P<0.05).</p><p><strong>Conclusions: </strong><i>VEGFC</i> may serve as an independent prognostic factor and potential immunotherapeutic target in HNSCC, offering insights into patient risk stratification and personalized treatment strategies.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"5953-5970"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of ferroptosis and pyroptosis model to assess the prognosis of gastric cancer patients based on bioinformatics.","authors":"Hanlu Shi, Hongfeng Yao, Yi Zhou, Gaoping Wu, Keyi Li, Lusheng Tang, Chen Yang, Dong Wang, Weidong Jin","doi":"10.21037/tcr-24-683","DOIUrl":"10.21037/tcr-24-683","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a malignancy with a grim prognosis, ranking as the second most common cause of cancer-related deaths globally. Various investigations have demonstrated the substantial involvement of ferroptosis and pyroptosis in the advancement of tumors. Nevertheless, the precise molecular mechanisms by which distinct genes associated with ferroptosis and pyroptosis influence the tumor microenvironment (TME) in GC remain elusive. Therefore, this study aims to elucidate the role of ferroptosis and pyroptosis in GC and provide insigths for GC therapy and prognosis evaluation.</p><p><strong>Methods: </strong>The data including gene expression, clinicopathological characteristics and survival information of GC samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts were collected, and the expression level of ferroptosis and pyroptosis genes (FPGs) in GC samples were analyzed. Consensus clustering analysis, Cox logistic regression, principal component analysis (PCA), and the \"survival\", \"survminer\", \"limma\", \"ggplot2\" and other packages in R were utilized to compare the differences among different groups. In the level of GC cells, cell viability experiments were conducted by Cell Counting Kit-8 (CCK-8) assay.</p><p><strong>Results: </strong>Through the analysis of the expression level of FPGs in GC samples from the TCGA and GEO cohorts, twenty-three prognostic-related and differentially expressed FPGs were collected for further analysis. Through consensus clustering analysis, three distinct patterns of FPGs were identified and found to be correlated with clinicopathological characteristics, immune cell infiltration, and prognosis in patients with GC. Subsequently, 684 prognostic-related genes from 1,082 pattern-related differentially expressed genes (DEGs) were screened for constructing the FPG_Score system to quantify FPGs patterns in individual GC patients and predict the prognosis. The analysis indicated that GC patients with high FPG_Score exhibited improved survival rates, increased tumor mutation burden (TMB), higher microsatellite instability (MSI), and elevated programmed cell death protein ligand 1 (PD-L1) expression. These patients with high FPG_Score were more likely to benefit from immunotherapy and had a more favorable prognosis.</p><p><strong>Conclusions: </strong>Our study innovatively provided a comprehensive analysis of FPGs in GC, and constructed the FPG_Score system for stratification of individual patients, so as to predict its benefit from immunotherapy and prognosis.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"5751-5770"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>SKA1/2/3</i> link to poor prognosis and immune infiltration of head and neck squamous cell carcinomas.","authors":"Churen Zhang, Jianguo Ke, Jia Li, Qiaoling Cai","doi":"10.21037/tcr-24-862","DOIUrl":"10.21037/tcr-24-862","url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinomas (HNSCs) are a diverse collection of tumors that originate in the oral cavity, pharynx, and larynx and pose a severe threat to human health, contributing to a fast-rising burden of cancer morbidity and mortality. The search for prognostic biomarkers of HNSC has been a hot topic. Spindle and kinetochore-associated (<i>SKA</i>) complex, including three members <i>SKA1/2/3</i>, which stabilize the spindle microtubules at the kinetosite during mitosis metaphase, has been demonstrated to be associated with poor prognosis of different cancers. The function of <i>SKA1/2/3</i> in HNSC remains to be investigated. We used a vast variety of public datasets and web-based technologies to investigate <i>SKA</i> complex expression and its link to patient prognosis, and discovered multiple pathways by which the <i>SKA</i> complex is regulated in HNSC.</p><p><strong>Methods: </strong>The Cancer Genome Atlas (TCGA) database was used to determine <i>SKA1/2/3</i> expression level in HNSC. <i>SKA1/2/3</i>-related proteins level and immune cells infiltration level were identified. Metascape was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. GSE31056 from Gene Expression Omnibus (GEO) database was used as an external dataset for data validation. A nomogram containing <i>SKA1/2/3</i> for the prognosis of HNSC patients was established.</p><p><strong>Results: </strong><i>SKA1/2/3</i> were highly expressed in HNSC. High expression of <i>SKA2</i> was significantly related to the poor overall survival (OS) and poor disease-free survival (DFS) of HNSC patients. <i>SKA1/2/3</i> and the related proteins were enriched in cell division, chromosome segregation, and mitotic cell cycle. <i>SKA1/2/3</i> expression was obviously positively correlated to several immune cells' infiltration. The expression values of <i>SKA1/2/3</i> were higher in tumors than in healthy tissues in GSE31056.</p><p><strong>Conclusions: </strong><i>SKA1/2/3</i> were shown to be related to the prognosis and immune cell infiltration of HNSC, which could be used as biological markers and therapeutic targets for HNSC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"6057-6069"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>SLC1A3</i> knockdown in inhibiting the proliferation, apoptosis resistance, and migration of ovarian cancer cells.","authors":"Wu Zhou, Yanqiang Xiong, Liangping Zhao, Gabriel Levin, Felipe Batalini, Zhihui Liu, Yuanxue Ma","doi":"10.21037/tcr-24-1909","DOIUrl":"10.21037/tcr-24-1909","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer accounts for 3% of all malignancies in women and kills about 140,000 women worldwide each year, representing the fifth leading cause of cancer-related death in women. At diagnosis, 70% of patients with ovarian cancer are already at stage III or IV disease, with a 5-year survival rate of less than 45%. Studies have found that solute carrier family 1 member 3 (<i>SLC1A3</i>) is highly expressed in various cancers and is associated with the poor prognosis of these cancers. However, the role of <i>SLC1A3</i> in ovarian cancer remains unknown. The purpose of this study was to investigate the role of the <i>SLC1A3</i> gene in the proliferation, apoptosis, migration, and outcomes of ovarian cancer.</p><p><strong>Methods: </strong>The expression level of <i>SLC1A3</i> was measured via quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Knockdown experiments were performed with small interfering RNA targeting <i>SLC1A3</i> in ovarian cancer cells. After the knockdown of <i>SLC1A3</i>, proliferation was evaluated with Cell Counting Kit 8 (CCK8) assay, apoptosis was measured by flow cytometry, and migration was evaluated via wound-healing assay. Kaplan-Meier method was used to analyze the effect of <i>SLC1A3</i> expression on the prognosis of patients with ovarian cancer.</p><p><strong>Results: </strong>High expression of <i>SLC1A3</i> was associated with poor prognosis in ovarian cancer patients, and the expression of <i>SLC1A3</i> in ovarian cancer cells was higher than that in ovarian epithelial cells. <i>In vitro</i> experiments demonstrated that knockdown of <i>SLC1A3</i> restrained the proliferation activity of ovarian cancer cells, enhanced cell apoptosis, and inhibited cell migration.</p><p><strong>Conclusions: </strong>High expression of <i>SLC1A3</i> is linked to poor prognosis in ovarian cancer patients. <i>SLC1A3</i> activity impedes apoptosis while enhancing the proliferation and migration of ovarian cancer cells, suggesting its potential as a therapeutic target for drug development.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"6315-6322"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"N-acetyltransferase 10 as a novel prognostic biomarker in papillary renal cell carcinoma: a machine learning and experimental validation study.","authors":"Liyang Li, Fan Li, Chenghao Zhou, Kangxin Ni, Haiyi Hu, Mingchao Wang, Huan Wang, Lei Gao","doi":"10.21037/tcr-2024-2195","DOIUrl":"10.21037/tcr-2024-2195","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;N-acetyltransferase 10 (&lt;i&gt;NAT10&lt;/i&gt;) is a lysine acetyltransferase known for catalyzing the N4-acetylcytidine (ac4C) modifications on RNAs. Recent studies have associated &lt;i&gt;NAT10&lt;/i&gt; with the pathogenesis of various cancers. However, its specific function and prognostic significance in papillary renal cell carcinoma (pRCC) remain poorly understood. This study aimed to explore &lt;i&gt;NAT10's&lt;/i&gt; prognostic value and mechanisms in pRCC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;&lt;i&gt;NAT10&lt;/i&gt; expression and prognostic associations in pancancer were analyzed using The Cancer Genome Atlas (TCGA). Single-cell RNA (scRNA) sequencing data from a previous study were used to characterize &lt;i&gt;NAT10&lt;/i&gt; expression at the single-cell level in pRCC. Pathway enrichment analysis, including gene set variance analysis (GSVA) and overrepresentation analysis, was conducted to investigate the potential mechanisms through which &lt;i&gt;NAT10&lt;/i&gt; exerts its effects. Immune cell infiltration analysis, conducted through the ESTIMATE and CIBERSORT algorithms, was performed to examine the association of &lt;i&gt;NAT10&lt;/i&gt; with the tumor microenvironment (TME). A &lt;i&gt;NAT10&lt;/i&gt;-related prognostic model was constructed using least absolute shrinkage and selection operator (LASSO) Cox regression on genes that were both positively correlated with &lt;i&gt;NAT10&lt;/i&gt; and were identified as &lt;i&gt;NAT10&lt;/i&gt;-mediated ac4C targets by ac4C RNA immunoprecipitation sequencing The model's performance was validated in the TCGA training set (n=285), with 42 events (deaths) and 243 censored cases, and in the GSE2748 external validation set (n=28), with 13 events (deaths) and 15 censored cases. The association between &lt;i&gt;NAT10&lt;/i&gt;-related risk scores and immunotherapy response was assessed via the IMvigor210 cohort. Finally, the aberrant expression of &lt;i&gt;NAT10&lt;/i&gt; was confirmed through immunohistochemistry data from the Human Protein Atlas database and our experimental validations from quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analyses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;&lt;i&gt;NAT10&lt;/i&gt; is upregulated in multiple cancers, including pRCC, and higher &lt;i&gt;NAT10&lt;/i&gt; expression correlates with advanced stages and poorer prognosis. Single-cell RNA-sequencing data confirmed elevated &lt;i&gt;NAT10&lt;/i&gt; expression in malignant pRCC cells. Pathway enrichment and immune cell infiltration analyses indicated that &lt;i&gt;NAT10&lt;/i&gt; is associated with malignancy-related pathways and a disordered TME. A prognostic model was constructed using LASSO Cox regression, with 18 core genes being identified, and demonstrated high predictive accuracy for survival. The model achieved AUC values of 0.97, 0.93, and 0.82 for 1-, 3-, and 5-year survival in the TCGA training set, respectively, while all AUC values in the GSE2748 external validation set were 1. Higher &lt;i&gt;NAT10&lt;/i&gt;-related risk scores were linked to poorer immunotherapy response in the IMvigor210 cohort. &lt;i&gt;NAT10&lt;/i&gt;'s prognostic significance wa","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"6364-6380"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PARP1 promotes tumor proliferation in lenalidomide-resistant multiple myeloma via the downregulation of microRNA-192-5p-AKT signaling.","authors":"Yuqing Luo, Yalu Chen, Cheng Ai, Xiaguang Huang, Fabiana Perna, Brandon J Kale, Say Min Lim, Meier Gu, Panpan Gao, Chunmeng Rong, Zefeng Zhou, Yiqin Weng, Yinyan Jiang, Fang Yang, Yongming Xia","doi":"10.21037/tcr-24-1543","DOIUrl":"10.21037/tcr-24-1543","url":null,"abstract":"<p><strong>Background: </strong>Lenalidomide-based therapies are recommended as first-line treatment for multiple myeloma (MM) patients, regardless of the transplant eligibility. Resistance to lenalidomide is a clinical problem that urgently needs to be addressed. The expression of poly(ADP-ribose) polymerase 1 (PARP1) is abnormally high in a variety of tumor tissues including MM. However, in lenalidomide-resistant MM, it is not yet known whether the abnormally high expression of PARP1 is involved in the occurrence of drug resistance, and whether the inhibition of PARP1 can reverse lenalidomide resistance. The aim of this study was to investigate the mechanism of PARP1 promoting lenalidomide-resistant in MM patients.</p><p><strong>Methods: </strong>Samples of bone marrow from patients with MM who were sensitive or resistant to lenalidomide were collected. The expression levels of PARP1 at the messenger RNA and protein levels were detected through polymerase chain reaction and western blot. MM cell lines were cultivated <i>in vitro</i>, cell lines resistant to lenalidomide were screened out, and the expression levels of PARP1 in the resistant cell lines were detected. The apoptosis level was also detected in the lenalidomide-resistant MM cell lines treated with a PARP1 inhibitor. The proliferation rates of the two groups of cells at different time points were evaluated by mono-methyl terephthalate (MMT) experiments. Finally, the effect of PARP1 on the proliferation of lenalidomide-resistant MM through the microRNA-192-5p-AKT signaling pathway was analyzed.</p><p><strong>Results: </strong>In the lenalidomide-resistant cell lines, the expression level of PARP1 was higher, the proliferation more rapid, and the apoptosis rate was lower than lenalidomide-sensitive cell lines. Additionally, the activated AKT pathway was suppressed by downregulating the expression of microRNA-192-5p. MM resistance can be inhibited to some extent by impacting PARP1.</p><p><strong>Conclusions: </strong>PARP1 is involved in the production of lenalidomide resistance in MM, and could serve as a potential target for the treatment of MM in the future.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"6273-6281"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.","authors":"Amir M Soltani-Tehrani, Aman Kumar, Kamal S Pohar","doi":"10.21037/tcr-24-180","DOIUrl":"10.21037/tcr-24-180","url":null,"abstract":"<p><p>Bladder cancer is a commonly diagnosed cancer, especially in men, and 70% of new diagnoses are considered non-muscle invasive bladder cancer (NMIBC). Bladder cancer is prone to high rates of recurrence, and this risk is greatest in high risk NMIBC. Intravesical bacillus Calmette-Guerin (BCG) is standard of care for reducing rates of recurrence for high risk NMIBC. Despite its favorable efficacy a significant proportion of patients do not have durable prolonged response to BCG and some patients progress to muscle invasive bladder cancer worsening prognosis. Predictive tools are needed in clinical practice to identify patients who are not likely to respond to BCG and need alternative treatments. The European Organization for Research and Treatment of Cancer (EORTC) and Club Urologico Espanol de Tratamiento Oncologico (CUETO) have proposed outcome prediction tables for NMIBC patients, providing risk stratification and recurrence and progression probability scores. While valuable in clinical practice, these tables have limitations and overestimate recurrence and progression for high risk NMIBC. Several efforts have attempted to refine our ability to better understand which patients derive the greatest benefit from BCG. T1 pathologic substaging, tumor budding, and artificial intelligence techniques studying pathologic features of the tumor and the microenvironment have been applied to high risk NMIBC as a means of identifying patients less likely to respond to BCG. Molecular markers, genomic alterations and transcriptomic signatures are promising and hold the potential to aid in forecasting tumor progression and response to therapy. However, their application is still in its initial phases and necessitates additional validation through further studies. This review describes both clinical and molecular risk factors that could prove beneficial in anticipating the response to BCG, with a particular focus on high-risk T1 bladder cancers.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"6489-6502"},"PeriodicalIF":1.5,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma.","authors":"","doi":"10.21037/tcr-2024-8","DOIUrl":"https://doi.org/10.21037/tcr-2024-8","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/tcr-24-269.].</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5719-5720"},"PeriodicalIF":1.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer.","authors":"Yunchao Wang, Yihan Zhao, Qing Liu, Jiwei Yang, Zhipeng Xu, Wenzhi Du, Guanbao Tang, Chuanpai Zhang, Xiaoqing Si, Jianning Wang","doi":"10.21037/tcr-23-2367","DOIUrl":"https://doi.org/10.21037/tcr-23-2367","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is the most common malignancy of the urinary tract and one of the most common cancers in the world. Cuproptosis is a novel type of cell death associated with tumorigenesis. In this study, we assessed the correlation between cuproptosis-related genes and tumorigenesis. Moreover, we constructed a prognostic signature.</p><p><strong>Methods: </strong>Pearson correlation analysis and univariate Cox regression were utilized to extract cuproptosis-related long non-coding RNAs (lncRNAs) predicting prognosis in The Cancer Genome Atlas (TCGA) database. The least absolute shrinkage and selection operator (LASSO) Cox regression was utilized to establish a cuproptosizs-related prognostic signature. A nomogram signature was generated to predict individual survival.</p><p><strong>Results: </strong>We obtained 19 cuproptosis-related genes and 14 prognostic cuproptosis-related lncRNAs. We constructed a seven-prognostic risk signature. Time-dependent receiver operating characteristic (ROC) curves demonstrated good predictive power (1-, 3-, and 5-year survival rates of 0.711, 0.673, and 0.684, respectively). The high-risk group reported a worse prognosis than the low-risk group, and the risk signature was identified as an independent factor. The biological process of risk-related genes primarily involved tumorigenesis and migration. The high-risk group expressed high chemokines and T cell inhibition and low antigen-presenting cells.</p><p><strong>Conclusions: </strong>Cuproptosis-related lncRNAs are central to tumorigenesis, providing a novel therapeutic target for patients with bladder cancer. We constructed an individualized predictive signature based on cuproptosis-related lncRNAs.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5178-5189"},"PeriodicalIF":1.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142627950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sini decoction-polysaccharide compound regulates proliferation, apoptosis, and glycolysis of liver cancer cells through PHLDA2/ANXA2.","authors":"Churan Shen, Peipei Huang, Wuji Xie, Xing Ni, Jingdong Gao","doi":"10.21037/tcr-24-1625","DOIUrl":"https://doi.org/10.21037/tcr-24-1625","url":null,"abstract":"<p><strong>Background: </strong>Sini decoction (SND), a popular formula from traditional Chinese medicine (TCM), plays a critical role in the treatment of liver disease. Its protective effect for the heart against cardiovascular diseases is well documented. However, its effects and pharmacological mechanisms for the liver remain unclear. This study aimed to clarify the effect and mechanism of the SND-polysaccharide compound (SNDPC) on hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>Different genes affected by SNDPC in HCC were analyzed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Databases including Multi-Experiment Matrix (MEM), HCCDB, LinkedOmics, and Gene Expression Profiling Interactive Analysis (GEPIA) were used to determine the correlation between <i>PHLDA2</i> and <i>ANXA2</i>. Cell proliferation and viability were identified using Cell Counting Kit-8 (CCK-8). Cell apoptosis was estimated using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and Western blotting. Glycolysis was determined by measuring glucose uptake, lactate concentration, extracellular acidification rate (ECAR), and the expressions of LHDA, HK2, and PKM2. The binding between PHLDA2 and ANXA2 was identified by coimmunoprecipitation.</p><p><strong>Results: </strong>SNDPC significantly weakened cell proliferation, facilitated cell apoptosis, and suppressed glycolysis by reducing glucose uptake, lactate concentration, ECAR, and the expressions of LDHA, HK2, and PKM2 in HCC cells. Furthermore, PHLDA2 was predicted to bind to ANXA2, which was confirmed by coimmunoprecipitation. SNDPC reduced the expressions of PHLDA2 and ANXA2 in HCCLM3 cells, and PHLDA2 silencing decreased the proliferation of cells, promoted cell apoptosis, and inhibited glycolysis of HCCLM3 cells while reversing the overexpression of PHLDA2.</p><p><strong>Conclusions: </strong>SNDPC suppressed proliferation and glycolysis while accelerating the apoptosis of HCC cells through PHLDA2/ANXA2.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5574-5587"},"PeriodicalIF":1.5,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}